Bristol Myers is the latest drug company to sue HHS over payment terms for 340B hospitals

Bristol Myers is the latest drug company to sue HHS over payment terms for 340B hospitals

Bristol wants to issue rebates for its Eliquis blood thinner, but the Biden administration maintained such a switch would violate federal law.

Bristol Myers is latest company to sue over payment terms for 340B hospitals

Bristol Myers Squibb has filed a lawsuit against the Biden administration for blocking the company from using rebates to pay hospitals in a federal drug discount program. This is the fourth pharmaceutical company to challenge payment terms recently. The lawsuit specifically involves Bristol’s Eliquis blood thinner. The U.S. Department of Health and Human Services rejected similar requests from Johnson & Johnson and Eli Lilly, who also filed laws…

4th drugmaker seeks 340B changes

As several pharmaceutical companies challenge their role in the 340B drug pricing program, Bristol Myers Squibb filed a lawsuit Nov. 26 against the HHS agency that oversees the federal program.

Bristol Myers sues the federal government over 340B, following other drugmakers

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model for distributing 340B drug discounts. Under the drugmaker's plan, hospitals and other covered entities would receive 340B discounts on its blood thinner Eliquis only after validating certain data, as opposed to upfront. Bristol Myers said the government’s disapproval of its rebate model is “unlawful three times over.” It ask…

House Places 340B Transparency Act on Floor Calendar, But a Vote is Not Guaranteed - 340B Report

More than a year after a key House panel passed legislation requiring 340B hospitals to report on a number of metrics regarding their 340B program use, lawmakers have placed the measure on a list of bills that could come up for floor consideration—however, it’s unlikely to clear Congress this session.